Dyax Corp $10.21

up +0.19


29/8/2014 04:00 PM  |  NASDAQ : DYAX  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get DYAX Trend Analysis - it has outperformed the S&P 500 by 103%

Partner Headlines

  1. FuelCell Upgrade; Amazon Announces New Product

    Benzinga
  2. SeaWorld Drops On Downbeat Results; Canadian Solar Shares Surge

    Benzinga
  3. Mid-Morning Market Update: Markets Gain; McDonald's Posts Lower Profit

    Benzinga
  4. Morning Market Movers

    Benzinga
  5. Dyax Receives FDA Approval to Expand Use of KALBITOR® (ecallantide) for ...

    Benzinga
  6. Mid-Day Market Update: Ulta Salon Jumps After Strong Earnings Report; Aeropostale ...

    Benzinga
  7. Mid-Morning Market Update: Markets Mixed; Ann To Lower Around 100 Jobs

    Benzinga
  8. Earnings Scheduled For February 28, 2014

    Benzinga
  9. Mornings Movers for Feb. 27, 2014: PEIX, JCP, SYMX, CIE, SHLD, BBY Higher, ...

    Benzinga
  10. Benzinga's Top #PreMarket Gainers

    Benzinga
  11. Lilly Drug Ramucirumab Boosts Lung Cancer Survival

    IBD
  12. Dyax Announces Positive DX-2930 and Biomarker Assay Data at ASH

    Benzinga
  13. Dyax Receives FDA Orphan Drug Designation for DX-2930 in Hereditary Angioedema ...

    Benzinga
  14. Stocks Hitting 52-Week Highs

    Benzinga
  15. Benzinga Weekly Preview: PMI Data In Focus

    Benzinga
  16. Dyax Announces Proposed Public Offering of Common Stock

    Benzinga
  17. Dyax Reports Dosing of First Subject in Phase 1 Trial of DX-2930

    Benzinga
  18. Dyax Corp. Reports Operating Results (10-Q)

    GuruFocus
  19. Stocks Hitting 52-Week Highs

    Benzinga
  20. Dyax Corp. Creates COO Position and Expands Executive Roles

    Benzinga
  21. Dyax Corp. Reports Operating Results (10-Q)

    GuruFocus
  22. Merck &, Quest Diagnostics Among Stocks Setting 52-Week Highs Thursday

    FoxBusiness
  23. Dyax Reports Results of Interim Analysis of Phase 2 Trial of Ecallantide ...

    Benzinga
Trading Center